Publication Name	World Journal of Gastroenterology
Manuscript ID	6785
Country	South Korea

Received	2013-10-29 09:38
Peer-Review Started	2013-10-29 22:39
To Make the First Decision	2013-12-26 11:37
Return for Revision	2013-12-27 15:10
Revised	2014-01-02 14:39
Second Decision	2014-04-03 10:07
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-04-03 11:30
Articles in Press	2014-05-23 11:03
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-04-17 15:55
Typeset the Manuscript	2014-06-05 09:32
Publish the Manuscript Online	2014-06-21 13:56

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Does antiviral therapy reduce complications of cirrhosis?
Manuscript Source	Invited Manuscript
All Author List	Goh Eun Chung, Jeong-Hoon Lee and Yoon Jun Kim
Funding Agency and Grant Number
Corresponding Author	Yoon Jun Kim, MD, PhD, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehang-no, Jongno-gu, Seoul 110-744, South Korea. yoonjun@snu.ac.kr
Key Words	Antiviral therapy; Cirrhosis; Complication; Hepatitis B; Decompensation
Core Tip	The goals of antiviral therapy in hepatitis B virus-related cirrhosis would be to improve the hepatic disease severity, improve the clinical symptoms and quality of life, and prolong patient’s survival. Despite the limitations, antiviral therapy with nucleos(t)ide in patients with HBV-related cirrhosis can prevent the development of complications from cirrhosis, particularly, decompensation and acute-on-chronic liver failure (ACLF). Early antiviral treatment is important for patients with severe decompensated cirrhosis and ACLF. Thus, physicians could treat these patients using lamivudine with careful monitoring for the development of resistance or using the most potent antiviral agent, such as entecavir or tenofovir.
Publish Date	2014-06-21 13:56
Citation	Chung GE, Lee JH, Kim YJ. Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol 2014; 20(23): 7306-7311
URL	http://www.wjgnet.com/1007-9327/full/v20/i23/7306.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i23.7306

Full Article (PDF)	WJG-20-7306.pdf
Full Article (Word)	WJG-20-7306.doc
Manuscript File	6785-Review.doc
Answering Reviewers	6785-Answering reviewers.pdf
Copyright License Agreement	6785-Copyright assignment.pdf
Peer-review Report	6785-Peer review(s).pdf
Scientific Editor Work List	6785-Scientific editor work list.doc